Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025